Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor

We examined the possible effects of a novel 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, rosuvastatin, on endothelial nitric oxide (NO) production and myocardial ischemia-reperfusion injury. Recent studies suggest that HMG-CoA reductase inhibitors promote vascular endothelial...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American College of Cardiology 2002-09, Vol.40 (6), p.1172-1178
Hauptverfasser:	Jones, Steven P, Gibson, Michael F, Rimmer, David M, Gibson, Terrie M, Sharp, Brent R, Lefer, David J
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Biological and medical sciences Cardiology Cardiotonic Agents - administration & dosage Cardiotonic Agents - pharmacology Cardiotonic Agents - therapeutic use Cardiovascular system Cholesterol Disease Models, Animal Dose-Response Relationship, Drug Endothelium, Vascular - drug effects Endothelium, Vascular - metabolism Fluorobenzenes - administration & dosage Fluorobenzenes - pharmacology Fluorobenzenes - therapeutic use Heart attacks Hemodynamics - drug effects Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Kinases Male Medical sciences Mice Mice, Inbred C57BL Miscellaneous Myocardial Reperfusion Injury - prevention & control Nitric oxide Nitric Oxide - metabolism Pharmacology. Drug treatments Pyrimidines Rosuvastatin Calcium Statins Sulfonamides Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!